Rose Conway Walsh (Sinn Fein) | Oireachtas source

I thank our guests for the work they do. I am following two drugs in particular, namely, Translarna and Spinraza. These drugs are what led me to the issue of rare diseases. I am not a permanent member of this committee. What has shocked me is the lack of transparency, which has been mentioned. Where there is no transparency, there is no trust. That is the real issue we need to tackle. The issues involve transparency, the delays and blockages in the system and how quickly we can get to a European situation where the BeNeLuxA benefits kick in and people really benefit from them. Are there specific actions we can take to bring transparency to the process?